TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the...

Area of Science:

• Urology
• Oncology
• Pharmacology

Background:

• High-risk non-muscle-invasive bladder cancer (NMIBC) poses challenges, particularly when unresponsive to bacillus Calmette-Guérin (BCG) therapy.
• Patients ineligible for or refusing radical cystectomy require alternative treatment strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of TAR-200, an intravesical gemcitabine drug-releasing system, in patients with BCG-unresponsive NMIBC.
• To assess TAR-200 alone or in combination with cetrelimab (a PD-1 inhibitor).

Main Methods:

• A phase IIb parallel cohort study involving patients with BCG-unresponsive carcinoma in situ (CIS) or papillary disease.
• Treatment arms included TAR-200 monotherapy, TAR-200 plus cetrelimab, and cetrelimab monotherapy.
• Primary endpoints were overall complete response (CR) rate and disease-free survival (DFS) rate.

Main Results:

• TAR-200 monotherapy showed an 82.4% CR rate in Cohort 2 and favorable 6-, 9-, and 12-month DFS rates in Cohort 4.
• Combination therapy (Cohort 1) and cetrelimab monotherapy (Cohort 3) also showed CR rates of 67.9% and 46.4%, respectively.
• Treatment-related adverse events were generally manageable, with TAR-200 monotherapy demonstrating a favorable risk-benefit profile.

Conclusions:

• TAR-200 monotherapy is well-tolerated, providing high CR rates and durable responses in BCG-unresponsive high-risk NMIBC.
• TAR-200 monotherapy appears to offer a superior risk-benefit profile compared to combination therapy or cetrelimab alone for BCG-unresponsive CIS.
• This study highlights TAR-200 as a promising therapeutic option for patients with challenging NMIBC.